Dr. Stephen Salloway. Photo: Brown/CNE
Butler Hospital in Providence announced on Monday that clinical trial results announced over the weekend and published in the New England Journal of Medicine (NEJM) indicate that the investigational drug donanemab holds promise as a potential treatment for early Alzheimer s disease.
Stephen Salloway, MD, MS, Director of the Memory and Aging Program and of Neurology at Butler Hospital and the Martin M. Zucker Professor of Psychiatry and Human Behavior and professor of Neurology at the Warren Alpert Medical School of Brown University, is a co-author of the NEJM article. GET THE LATEST BREAKING NEWS HERE SIGN UP FOR GOLOCAL FREE DAILY EBLAST